Oncoprecision Corporation

Oncoprecision Corporation is a biotechnology firm specializing in the development of innovative therapeutic antibodies, with a focus on enhancing drug discovery through patient-centered approaches and advanced modeling techniques. Founded in 2020 and headquartered in New York, US, Oncoprecision Corporation is dedicated to developing therapeutic solutions in oncology. The company was founded by Candelaria De Los Ríos, Gastón Soria, Gerardo Gatti, and Tarek Zaki, who also serves as CEO. Oncoprecision has successfully raised USD 3.

3 mn in Seed funding, with the latest investment round completed on April 1, 2022. Investors in this round included Creative Ventures, FPM, Fundación Para el Progreso de la Medicina, GRID EXPONENTIAL, New York Ventures, and SOSV. The company has completed 2 deals to date, focusing on the strategic development of their innovative product pipeline. Oncoprecision is focused on developing novel therapeutic antibodies using a patient-centric approach in drug discovery.

Their proprietary patient-derived models enhance the understanding of translational biology and improve success rates in drug development. Their product pipeline includes ONC001, an antibody-drug conjugate for monocytic leukemia, and ONC002, a bispecific antibody targeting tumor-associated macrophages. The company primarily collaborates with pharmaceutical partners and cancer research institutions across North and South America. Oncoprecision generates revenue through strategic partnerships and collaborations with leading pharmaceutical companies and cancer centers.

These collaborations typically involve licensing agreements that provide clients access to Oncoprecision’s proprietary models and therapeutic capabilities, structured around milestones and royalties. Their flagship products, including ONC001 and ONC002, contribute significantly to revenue through clinical validation studies and partnerships aimed at developing new cancer therapies. To support its future growth, Oncoprecision plans to utilize the recently acquired USD 3. 3 mn from the Seed funding round raised in October 2022 to further develop its technology.

The company aims to expand its product offerings and explore new markets, particularly in North America and South America, by leveraging their innovative therapeutic models. Upcoming product launches are expected to enhance their portfolio and address critical needs in oncology.